![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1416195
½ÉÀåÀ絿±âÈ¿ä¹ý(CRT) ±â±â ½ÃÀå : Á¦Ç°º°, ¿¬·Éº°, ÃÖÁ¾ ¿ëµµº° Àü¸Á(2023-2032³â)Cardiac Resynchronisation Therapy (CRT) Devices Market - By Product (CRT-P, CRT-D), By Age (Below 44 Years, 45- 64 Years, 65-84 Years, Above 85 Years), By End-use & Forecast, 2023 - 2032 |
¼¼°è ½ÉÀåÀ絿±âÈ¿ä¹ý(CRT) ±â±â ½ÃÀåÀº ÀÇ·á ±â¼ú ¹ßÀü, ½ÉºÎÀü À¯º´·ü Áõ°¡, ȯÀÚ ¹× ÀÇ·áÁøÀÇ ÀÎ½Ä Á¦°í µîÀ» ¹è°æÀ¸·Î 2023³âºÎÅÍ 2032³â±îÁö 5.9%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Radcliffe Cardiology°¡ 2023³â¿¡ ¹ßÇ¥ÇÑ ¿¬±¸¿¡ µû¸£¸é, ½ÉºÎÀü(HF)Àº Àü ¼¼°èÀûÀ¸·Î ¾à 6400¸¸ ¸íÀÌ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µÇ´Â ¼¼°è °øÁߺ¸°Ç ¹®Á¦ÀÔ´Ï´Ù. °í·ÉÈÀ²ÀÌ Áõ°¡ÇÏ°í »ýȰ ½À°üÀÌ ½ÉÀå °ü·Ã ¹®Á¦¸¦ À¯¹ßÇÏ´Â ¿äÀÎÀÌ µÇ¸é¼ °í±Þ ½ÉÀå °ü¸® ¼Ö·ç¼ÇÀÇ Çʿ伺ÀÌ ´õ¿í ºÎ°¢µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÉÀå À絿±âÈ Ä¡·áÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀÇ·á Àü¹®°¡¿Í ȯÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¾÷°è ¼ºÀå¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.
¼¼°è CRT ÀåÄ¡ ½ÃÀåÀº Á¦Ç°, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.
CRT ½É¹ÚÁ¶À²±â ºÐ¾ß´Â ½ÉÀå µ¿±âÈ °È, ÆäÀÌ½Ì ¹× À絿±âÈ ÀÌÁß ±â´É, ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ Á¶»ç ±â°£ µ¿¾È ¾ÈÁ¤ÀûÀÎ ¼Óµµ·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÆäÀ̰̽ú À絿±âÈ ¿ä±¸¸¦ ¸ðµÎ ÃæÁ·ÇÏ´Â ÀÌÁß ±â´ÉÀº º¹ÀâÇÑ ½ÉÀå Ä¡·á ¼ö¿ä¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ °í±Þ ½ÉÀå °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â Á¦Ç° ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
½ÉÀå Ä¡·á ¼¾ÅÍÀÇ ÃÖÁ¾ ¿ëµµ ºÐ¾ß´Â Á¾ÇÕÀûÀÎ ½ÉÀå Ä¡·á ¼ºñ½º¿Í ¿ª·® °È·Î 2032³â±îÁö ²ÙÁØÇÑ ¼ºÀå ¸ð¸àÅÒÀ» À¯ÁöÇϰí ÀÖ½À´Ï´Ù. ½ÉÀå Ä¡·á ¼¾Åʹ ȯÀÚ Áß½ÉÀÇ °³º° Ä¡·á¸¦ ¿ì¼±½ÃÇÏ¿© ÀÇ·á ºÐ¾ß¿¡¼ ¸Å·ÂÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ±â¼úÀ» ½ÉÀå Ä¡·á ¼¾ÅÍ¿¡ ÅëÇÕÇÏ¿© Á¢±Ù¼ºÀ» ³ôÀ̰í ȯÀÚ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉÀå À絿±âÈ Ä¡·á ±â±â ½ÃÀåÀº 2023³âºÎÅÍ 2032³â±îÁö °·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â Áß±¹, Àεµ¿Í °°Àº ±¹°¡¿¡¼ ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë¿Í ÇÔ²² ½ÉÇ÷°ü ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ Áö¿ª¿¡¼´Â ÇコÄÉ¾î ºÐ¾ßÀÇ ±Þ¼ÓÇÑ ±â¼ú ¹ßÀüÀÌ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, ÀÌ ºÐ¾ß¿¡ À¯¸®ÇÑ È¯°æÀÌ Á¶¼ºµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ½Ã½ºÅÛÀÌ È¯ÀÚ °á°ú °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃß°í Àֱ⠶§¹®¿¡ R&D ÀÌ´Ï¼ÅÆ¼ºê¿¡ ´ëÇÑ ÀÚ±ÝÀÌ ½ÃÀå Àü¸ÁÀ» Çü¼ºÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
The global Cardiac Resynchronization Therapy (CRT) Devices Market is anticipated to expand at 5.9% during 2023-2032, driven by advancements in medical technology, increasing prevalence of heart failure, and growing awareness amongst patients & healthcare professionals.
According to a study published by Radcliffe Cardiology in 2023, Heart failure (HF) is an escalating global public health concern, affecting an estimated 64 million people worldwide. As the aging population proportion grows and lifestyle factors contribute to heart-related issues, the need for advanced cardiac care solutions becomes more pronounced. Additionally, the growing awareness among healthcare professionals and patients about the benefits of cardiac resynchronization therapy further fuels industry growth.
The global CRT devices market is classified based on product, end-use, and region.
The CRT-pacemakers segment is expected to expand at a steady pace during the study period driven by enhanced cardiac synchronization, dual functionality in pacing & resynchronization and technological advancements. The dual functionality, addressing both pacing and resynchronization needs, positions them as comprehensive solutions for the intricate demands of cardiac care. Moreover, the growing demand for advanced cardiac care solutions has further propelled product demand.
Cardiac care centers end-use segment is gaining momentum for steady growth through 2032, driven by comprehensive cardiac care services and capability enhancement. Cardiac care centers prioritize individualized, patient-centric care, boosting their appeal in the healthcare sector. Moreover, the integration of telemedicine and remote monitoring technologies in cardiac care centers enhances accessibility and improves patient outcomes.
Asia Pacific cardiac resynchronization therapy devices market is set for robust growth during 2023 and 2032, attributed to the increasing incidence of cardiovascular diseases, coupled with the expanding healthcare infrastructure in countries like China and India. The region is witnessing rapid technological advancements in the healthcare sector, creating a conducive environment for the sector. Moreover, as healthcare systems focus on improving patient outcomes, the funding for R&D initiatives will shape the market outlook.